February 25th, 2009
Antidepressant drugs, already known to cause sexual side effects, may also suppress the basic human emotions of love and romance.
That SSRIs, or selective serotonin reuptake inhibitors — the most common type of antidepressant — cause sexual dysfunction is common knowledge. Of the 31 million adults in the United States who take the SSRIs, about 30 percent are believed to experience sexual dysfunction.
But a new theory suggests that SSRI antidepressants may also subtly alter the fundamental chemistry of love and romance, snuffing the first sparks between two people otherwise destined to become lovers, and preventing couples from bonding.
For some people, of course, sexual side effects are an acceptable price to pay for curing debilitating depression. But as antidepressant use becomes more common, extending beyond full-blown clinical depression to disorders like anxiety and, in some cases, insomnia, the possibility of love-stunting is troubling.
SSRI antidepressants work by boosting circulating levels of serotonin, a mood-regulating neurotransmitter that also inhibits desire. The drugs also decrease dopamine, a neurotransmitter involved in a wide range of cognitive and behavioral processes, among them desire and arousal. The new research suggests that dopamine may also play a part in romance.
During sex, a cocktail of hormones is released that appears to play important roles in fostering romantic attachment within the brain. Take away sex, and romantic love can dwindle. But this is just part of the problem, say Fisher and University of Virginia psychiatrist James Thomson.
Dopamine also appears central to the neurobiology of romantic love and attachment, conditions that Fisher believes to be affected by — but ultimately distinct from — sexual love and its effects. She and Thomson say that SSRIs may do more than cause sexual dysfunction: They also suppress romance.
“There are all sorts of unconscious systems in our brain that we use to negotiate romantic love and romantic attraction,” said Thomson. “If these drugs cause conscious sexual side effects, we’d argue that there are going to be side effects that are not conscious.”
According to Fisher, humans have three distinct but interconnected love-related brain systems: one for sex, another for attachment and another for romantic love. This is still hypothetical — nobody knows exactly what love does in the brain — but Fisher has been a pioneering researcher on romantic love’s neurobiology, and dopamine indeed appears important.
When couples have just fallen in love, the mere sight of the other causes a jump in dopamine-related brain activity. If they manage to stay in love, with the early flush giving way to long-term affection, those brain patterns stay active.
Reduced dopamine levels, however, are an inevitable effect of SSRIs. Reduce dopamine, say Fisher and Thomson, and the possibility of love itself is reduced.
Though biologically plausible, definitive evidence for this has yet to be found. The only study to specifically test the hypothesis was conducted by Saint Mary’s University psychologist Maryanne Fisher, who found that women taking antidepressants tended to have muted reactions when showed pictures of attractive men. The effect was small, however, and the study has not been reproduced.
University of California at Los Angeles psychiatrist Andrew Leuchter acknowledged that increasing serotonin can decrease dopamine, but has not seen difficulties in forming emotional attachments among his patients. “I’ve seen people who have great difficulty with their emotional attachments, who think they’ve fallen out of love or want to isolate themselves, come alive again,” said Leuchter, who receives funding from antidepressant drugmakers. “I’m not sure the syndrome [Fisher and Thomson] describe exists.”
Thomson and Fisher, on the other hand, report the opposite: antidepressant takers who’ve lost the capacity for romantic feeling.
Clinical studies of antidepressant side effects do little to settle this debate. They’ve focused on sexual problems, which are far easier to measure than subtle effects on something so ephemeral as a spark.
Thomson recommended that psychologists investigating romance ask test subjects whether they take antidepressants. He also suggests that the possibility of romantic stunting be considered when deciding whether antidepressants should be prescribed to a child or young adult.
“Does it impact the development of those areas of the brain involved in love and sexuality? Does it impair the feelings and behaviors of romantic love and sexuality and the learning processes, which might be required to bring those areas of the brain online?” said Thomson. “We don’t know.”
Said Fisher, “We want to know about the side effects of other drugs. Why not know about the side effects of these drugs, which affect our reproductive future?”
Another alternative could be drugs that don’t boost serotonin. Bupropion, also known as Wellbutrin, increases levels of dopamine and norepinephrine, another neurotransmitter; it’s been associated with far lower levels of sexual dysfunction, but doesn’t work for everyone.
Drug companies are currently designing next-generation antidepressants that raise dopamine, serotonin and norepinephrine levels simultaneously, and might have fewer romantic side effects. However, none of these drugs are yet on the market, and projected side effects remain hypothetical.
“Any drug in development is always better than anything out there,” said Leuchter. “And then, once they hit the market, nothing is perfect.”